$BFRI
Biofrontera Inc. Stock $bfri

$bfri Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040132 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$10.60M	$8.896M	$4.322M
YoY Change	4.46%	105.83%	-0.28%
Cost Of Revenue	$5.368M	$4.590M	$2.225M
YoY Change	2.13%	106.29%	-2.84%
Gross Profit	$5.228M	$4.310M	$2.097M
YoY Change	6.96%	105.53%	2.59%
Gross Profit Margin	49.34%	48.45%	48.52%
Selling, General & Admin	$9.060M	$8.619M	$7.765M
YoY Change	-11.25%	11.0%	-54.99%
% of Gross Profit	173.3%	199.98%	370.29%
Research & Development		$33.00K
YoY Change
% of Gross Profit		0.77%
Depreciation & Amortization	$125.0K	$130.0K	$131.0K
YoY Change	0.0%	-0.76%	-2.24%
% of Gross Profit	2.39%	3.02%	6.25%
Operating Expenses	$9.060M	$13.52M	$7.961M
YoY Change	-13.78%	69.78%	-55.65%
Operating Profit	-$3.832M	-$4.620M	-$3.639M
YoY Change	-31.81%	26.96%	-77.12%
Interest Expense	-$998.0K	$142.0K	$89.00K
YoY Change	2751.43%	59.55%	-203.49%
% of Operating Profit
Other Income/Expense, Net	$998.0K	-$1.721M	$1.074M
YoY Change	-65.24%	-260.24%	480.54%
Pretax Income	$3.520M	-$6.341M	-$2.565M
YoY Change	-226.44%	147.21%	-83.97%
Income Tax	-$6.000K	$1.000K	$1.000K
% Of Pretax Income	-0.17%
Net Earnings	$3.526M	-$6.342M	-$2.566M
YoY Change	-226.61%	147.16%	-83.97%
Net Earnings / Revenue	33.28%	-71.29%	-59.37%
Basic Earnings Per Share		-$4.64	-$0.11
Diluted Earnings Per Share	$2.28	-$4.64	-$0.11
COMMON SHARES
Basic Shares Outstanding	1.518M shares	1.368M shares	23.55M shares
Diluted Shares Outstanding		1.367M shares	22.73M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.421M	$6.760M	$27.60M
YoY Change	-94.9%	-75.51%	1402.61%
Cash & Equivalents	$1.343M	$3.422M	$27.50M
Short-Term Investments	$78.00K	$3.340M	$85.00K
Other Short-Term Assets	$5.584M	$270.0K	$721.0K
YoY Change	670.21%	-62.55%	-11.53%
Inventory	$10.91M	$16.07M	$12.09M
Prepaid Expenses	$305.0K		$460.0K
Receivables	$5.162M	$6.510M	$5.065M
Other Receivables	$0.00	$0.00	$3.017M
Total Short-Term Assets	$23.08M	$29.61M	$48.49M
YoY Change	-46.51%	-38.94%	378.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.746M	$154.0K	$224.0K
YoY Change	755.88%	-31.25%	-22.49%
Goodwill
YoY Change
Intangibles	$2.629M	$2.718M	$3.136M
YoY Change	-13.29%	-13.33%
Long-Term Investments
YoY Change
Other Assets	$482.0K	$490.0K	$393.0K
YoY Change	50.63%	24.68%	-71.38%
Total Long-Term Assets	$4.857M	$4.493M	$6.566M
YoY Change	-37.28%	-31.57%	25.86%
TOTAL ASSETS
Total Short-Term Assets	$23.08M	$29.61M	$48.49M
Total Long-Term Assets	$4.857M	$4.493M	$6.566M
Total Assets	$27.93M	$34.10M	$55.06M
YoY Change	-45.11%	-38.06%	258.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.006M	$8.620M	$253.0K
YoY Change	604.69%	3307.11%	-87.53%
Accrued Expenses	$4.492M	$11.04M	$9.442M
YoY Change	-58.65%	16.91%	6.85%
Deferred Revenue
YoY Change
Short-Term Debt	$3.904M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.09M	$29.12M	$17.14M
YoY Change	-13.43%	69.89%	51.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.051M	$38.00K	$5.646M
YoY Change	23952.38%	-99.33%	-73.67%
Total Long-Term Liabilities	$5.051M	$38.00K	$5.646M
YoY Change	23952.38%	-99.33%	-73.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.09M	$29.12M	$17.14M
Total Long-Term Liabilities	$5.051M	$38.00K	$5.646M
Total Liabilities	$23.14M	$33.07M	$32.46M
YoY Change	-14.32%	1.85%	-0.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$99.70M	-$103.2M	-$76.70M
YoY Change	25.41%	34.55%
Common Stock	$2.000K	$1.000K	$23.00K
YoY Change	-92.59%	-95.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.793M	$1.038M	$22.60M
YoY Change
Total Liabilities & Shareholders Equity	$27.93M	$34.10M	$55.06M
YoY Change	-45.11%	-38.06%	258.6%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	$3.526M	-$6.342M	-$2.566M
YoY Change	-226.61%	147.16%	-83.97%
Depreciation, Depletion And Amortization	$125.0K	$130.0K	$131.0K
YoY Change	0.0%	-0.76%	-2.24%
Cash From Operating Activities	-$8.866M	-$2.000M	-$5.941M
YoY Change	7.19%	-66.34%	388.17%
INVESTING ACTIVITIES
Capital Expenditures	-$9.000K	$0.00	-$1.000K
YoY Change	-1000.0%	-100.0%	-200.0%
Acquisitions
YoY Change
Other Investing Activities	$64.00K	$380.0K	-$3.033M
YoY Change	-103.07%	-112.53%
Cash From Investing Activities	$73.00K	$390.0K	-$3.034M
YoY Change	-103.5%	-112.85%	-303500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.714M	590.0K	4.630M
YoY Change		-87.26%	-3926.45%
NET CHANGE
Cash From Operating Activities	-8.866M	-2.000M	-5.941M
Cash From Investing Activities	73.00K	390.0K	-3.034M
Cash From Financing Activities	6.714M	590.0K	4.630M
Net Change In Cash	-2.079M	-1.020M	-4.345M
YoY Change	-79.93%	-76.52%	224.98%
FREE CASH FLOW
Cash From Operating Activities	-$8.866M	-$2.000M	-$5.941M
Capital Expenditures	-$9.000K	$0.00	-$1.000K
Free Cash Flow	-$8.857M	-$2.000M	-$5.940M
YoY Change	7.07%	-66.33%	387.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001858685
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q3	BFRI	Warrant Inducement Expense WarrantInducementExpense		usd
	BFRI	Warrant Inducement Expense WarrantInducementExpense		usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2023Q3	BFRI	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	BFRI	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	BFRI	Warrant Inducement Expense WarrantInducementExpense		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
	BFRI	Disbursement For Loan Receivable DisbursementForLoanReceivable		usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
	BFRI	Proceeds From Exercise Of Warrants ProceedsFromExerciseOfWarrants		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	BFRI	Interest Paid Related Party InterestPaidRelatedParty		usd
	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity		usd
	BFRI	Addition Of Rightofuse Assets In Exchange For Operating Lease Liabilities AdditionOfRightofuseAssetsInExchangeForOperatingLeaseLiabilities		usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q3	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold		usd
	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold		usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q3	BFRI	Interest Expenses Related Party InterestExpensesRelatedParty		usd
	BFRI	Interest Expenses Related Party InterestExpensesRelatedParty		usd
CY2023Q3	us-gaap	Interest Income Operating InterestIncomeOperating		usd
	us-gaap	Interest Income Operating InterestIncomeOperating		usd
CY2023Q3	BFRI	Stock Options And Restricted Stock Units StockOptionsAndRestrictedStockUnits		shares
CY2022Q3	BFRI	Stock Options And Restricted Stock Units StockOptionsAndRestrictedStockUnits		shares
	BFRI	Stock Options And Restricted Stock Units StockOptionsAndRestrictedStockUnits		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40943
	dei	Entity Registrant Name EntityRegistrantName	Biofrontera Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3765675
	dei	Entity Address Address Line1 EntityAddressAddressLine1	120 Presidential Way
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 330
	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
	dei	City Area Code CityAreaCode	(781)
	dei	Local Phone Number LocalPhoneNumber	245-1325
	dei	Entity Information Former Legal Or Registered Name EntityInformationFormerLegalOrRegisteredName	Not Applicable
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1517628	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3422000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17208000	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	3793000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3748000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	16068000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7168000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	274000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	810000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	29611000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43140000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	154000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	204000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1129000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1375000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2718000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3032000	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	492000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	320000	usd
CY2023Q3	us-gaap	Assets Assets	34104000	usd
CY2022Q4	us-gaap	Assets Assets	50884000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7211000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6942000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	555000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	11039000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10864000	usd
CY2023Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1697000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	29124000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20894000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2500000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2400000	usd
CY2023Q3	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	842000	usd
CY2022Q4	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	2843000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	562000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	848000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	33066000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	27006000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1367628	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1367628	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1334950	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1334950	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104213000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103396000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103176000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79519000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1038000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34104000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50884000	usd
CY2023Q3	BFRI	Products Revenues Net ProductsRevenuesNet	8879000	usd
CY2022Q3	BFRI	Products Revenues Net ProductsRevenuesNet	4290000	usd
	BFRI	Products Revenues Net ProductsRevenuesNet	23423000	usd
	BFRI	Products Revenues Net ProductsRevenuesNet	18467000	usd
CY2023Q3	BFRI	Revenues Related Party RevenuesRelatedParty	17000	usd
CY2022Q3	BFRI	Revenues Related Party RevenuesRelatedParty	32000	usd
	BFRI	Revenues Related Party RevenuesRelatedParty	52000	usd
	BFRI	Revenues Related Party RevenuesRelatedParty	63000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8896000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4322000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23475000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18530000	usd
CY2023Q3	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	4495000	usd
CY2022Q3	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	2127000	usd
	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	11814000	usd
	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	9504000	usd
CY2023Q3	BFRI	Cost Of Revenues CostOfRevenues	95000	usd
CY2022Q3	BFRI	Cost Of Revenues CostOfRevenues	98000	usd
	BFRI	Cost Of Revenues CostOfRevenues	262000	usd
	BFRI	Cost Of Revenues CostOfRevenues	425000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8619000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7765000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29874000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25050000	usd
CY2023Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	74000	usd
CY2022Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	171000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	193000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	612000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	200000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2200000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4100000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	13516000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	7961000	usd
	us-gaap	Operating Expenses OperatingExpenses	42287000	usd
	us-gaap	Operating Expenses OperatingExpenses	31491000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4620000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3639000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18812000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12961000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-598000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3814000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2001000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-17896000	usd
CY2022Q3	BFRI	Warrant Inducement Expense WarrantInducementExpense	2629000	usd
	BFRI	Warrant Inducement Expense WarrantInducementExpense	2629000	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2212000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-6635000	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-142000	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-89000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-256000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-160000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	65000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1721000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1074000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4825000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15137000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6341000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2565000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23637000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2176000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6342000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2566000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23657000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2145000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.64
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.19
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.64
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.19
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1366842	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1136291	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1346264	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	978018	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1366842	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1136291	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1346264	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	980251	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7173000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	207000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6342000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1038000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	817000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23657000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1038000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	17233000	usd
CY2022Q3	BFRI	Stock Issued During Period Value Exercise Of Prefunded Warrants StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants	2841000	usd
CY2022Q3	BFRI	Stock Issued During Period Value Exercise Of Pipe Warrants StockIssuedDuringPeriodValueExerciseOfPipeWarrants	4686000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	401000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2566000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22595000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11338000	usd
	BFRI	Stock Issued During Period Value Private Placement Offering StockIssuedDuringPeriodValuePrivatePlacementOffering	116000	usd
	BFRI	Stock Issued During Period Value Exercise Of Prefunded Warrants StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants	2841000	usd
	BFRI	Stock Issued During Period Value Exercise Of Pipe Warrants StockIssuedDuringPeriodValueExerciseOfPipeWarrants	4686000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1469000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2145000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2145000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22595000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23657000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2145000	usd
	us-gaap	Depreciation Depreciation	65000	usd
	us-gaap	Depreciation Depreciation	80000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	390000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	314000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	314000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6635000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4100000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2001000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-17896000	usd
	BFRI	Warrant Inducement Expense WarrantInducementExpense	2629000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	817000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1469000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	100000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	158000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	111000	usd
	BFRI	Noncash Interest Expense NoncashInterestExpense	296000	usd
	BFRI	Noncash Interest Expense NoncashInterestExpense	268000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	204000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2111000	usd
	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-3652000	usd
	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-5145000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-347000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4121000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8900000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7728000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	6137000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	3519000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-375000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	197000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-216000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16029000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7928000	usd
	BFRI	Disbursement For Loan Receivable DisbursementForLoanReceivable	3033000	usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	560000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	546000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3070000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	13546000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9391000	usd
	BFRI	Proceeds From Exercise Of Warrants ProceedsFromExerciseOfWarrants	4630000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	11849000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1697000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14021000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13786000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3023000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17408000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24742000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3622000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27765000	usd
	us-gaap	Interest Paid Net InterestPaidNet	31000	usd
	us-gaap	Interest Paid Net InterestPaidNet	10000	usd
	BFRI	Interest Paid Related Party InterestPaidRelatedParty	22000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	21000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	30000	usd
	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	6840000	usd
	BFRI	Addition Of Rightofuse Assets In Exchange For Operating Lease Liabilities AdditionOfRightofuseAssetsInExchangeForOperatingLeaseLiabilities	147000	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-20
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	100.00
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3400000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17200000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18800000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13000000.0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16000000.0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7900000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103200000	usd
CY2023Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	4100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zCAgLbUTYIS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_862_zpNXuh5tGh8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to, valuation allowances for receivables and inventory, valuation of contingent consideration and warrant liabilities, realization of intangible and other long-lived assets, product sales allowances and reserves, share-based payments and income taxes including deferred tax assets and liabilities. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2500000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
CY2023Q3	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2500000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
CY2023Q3	BFRI	Startup Cost Financing StartupCostFinancing	7300000	usd
CY2022Q4	BFRI	Startup Cost Financing StartupCostFinancing	7300000	usd
CY2023Q3	BFRI	Contract Asset ContractAsset	-89000	usd
CY2022Q4	BFRI	Contract Asset ContractAsset	-358000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9711000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9342000	usd
CY2023Q3	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	5745678	shares
CY2022Q4	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	6446946	shares
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	usd
CY2023Q3	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2500000	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	6200000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4100000	usd
CY2022Q3	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2100000	usd
CY2021Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	246000	usd
	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	691000	usd
	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	577000	usd
CY2022Q3	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	360000	usd
CY2022Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	82000	usd
CY2022Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	82000	usd
	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	429000	usd
	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	378000	usd
CY2023Q3	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	133000	usd
CY2023Q3	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	133000	usd
CY2023Q3	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	5745678	shares
CY2022Q4	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	6446946	shares
	us-gaap	Equity Method Investment Additional Information EquityMethodInvestmentAdditionalInformation	3,377,346
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	600000	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2212000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6635000	usd
CY2023Q3	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold	-345000	usd
	BFRI	Net Losses Recognized During Period On Equity Securities Sold NetLossesRecognizedDuringPeriodOnEquitySecuritiesSold	-420000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1867000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-6215000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	200000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	usd
CY2023Q3	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1882000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1568000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2718000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3032000	usd
CY2023Q3	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	250000	usd
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	3000000.0	usd
	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	650000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3422000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17208000	usd
CY2023Q3	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3622000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17408000	usd
CY2023Q3	BFRI	Legal Settlement Expenses Current LegalSettlementExpensesCurrent	6028000	usd
CY2022Q4	BFRI	Legal Settlement Expenses Current LegalSettlementExpensesCurrent	6207000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2948000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2850000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1253000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1353000	usd
CY2023Q3	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	134000	usd
CY2022Q4	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	82000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	676000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	372000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11039000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10864000	usd
CY2023Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0548	pure
CY2023Q3	us-gaap	Line Of Credit LineOfCredit	200000	usd
CY2023Q3	BFRI	Legal Settlements Receivable Percentage LegalSettlementsReceivablePercentage	0.50	pure
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-20
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	86951	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	22477	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	31480	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	53.58
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	77948	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	51.74
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M12D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	24210	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	62.23
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1000000.0	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2023Q3	BFRI	Interest Expenses InterestExpenses	43000	usd
CY2022Q3	BFRI	Interest Expenses InterestExpenses	3000	usd
	BFRI	Interest Expenses InterestExpenses	77000	usd
	BFRI	Interest Expenses InterestExpenses	10000	usd
CY2023Q3	BFRI	Interest Expenses Related Party InterestExpensesRelatedParty	22000	usd
	BFRI	Interest Expenses Related Party InterestExpensesRelatedParty	22000	usd
CY2023Q3	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	90000	usd
CY2022Q3	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	89000	usd
	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	268000	usd
	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	268000	usd
CY2022Q3	us-gaap	Interest Income Operating InterestIncomeOperating	1000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	110000	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	13000	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	2000	usd
	us-gaap	Interest Income Other InterestIncomeOther	111000	usd
	us-gaap	Interest Income Other InterestIncomeOther	8000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	142000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	89000	usd
	us-gaap	Interest Expense InterestExpense	256000	usd
	us-gaap	Interest Expense InterestExpense	160000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6342000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2566000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23657000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2145000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1366842	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1136291	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1346264	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	978018	shares
	BFRI	Stock Options And Restricted Stock Units StockOptionsAndRestrictedStockUnits	2233	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1366842	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1136291	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1346264	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	980251	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.64
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.19
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.64
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.19
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	option to extend the term of the lease for one five (5) year period
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	390000	usd
	BFRI	Interest On Lease Liabilities InterestOnLeaseLiabilities	54000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	444000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	428000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0675	pure
CY2023Q3	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	171000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	584000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	393000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	44000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1193000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	76000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1117000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	555000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	562000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1117000	usd
CY2021Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	22500000	usd
	us-gaap	Description Of Nature And Effect Of Significant Changes During Period Affecting Comparability DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability	The Company matches 50% of employee contributions up to a maximum of 6% of employees’ salary.
CY2023Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
CY2022Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
	us-gaap	Reclassifications Reclassifications	<p id="xdx_80A_eus-gaap--Reclassifications_zOLWREpE2sbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>20. <span id="xdx_82F_zqM3M0HqA2n6">Reclassification of Prior Year Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year amounts have been reclassified to their own line items within the Consolidated Statement of Operations and Consolidated Statements of Cash Flow. Specifically, warrant inducement expense of $<span id="xdx_90B_eus-gaap--DeferredSalesInducementsAmortizationExpense_pn5n6_c20230101__20230930_zNE10GY7GJz" title="Inducement expense">2.6</span> million was reclassed from change in fair value of warrant liabilities for prior year presentation. These reclassifications had no effect on the reported results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	2600000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2027-11-18
CY2022Q3	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2026-12-01

Files In Submission

Name	View Source	Status
0001493152-23-040132-index-headers.html	Edgar Link	pending
0001493152-23-040132-index.html	Edgar Link	pending
0001493152-23-040132.txt	Edgar Link	pending
0001493152-23-040132-xbrl.zip	Edgar Link	pending
bfri-20230930.xsd	Edgar Link	pending
bfri-20230930_def.xml	Edgar Link	unprocessable
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bfri-20230930_cal.xml	Edgar Link	unprocessable
bfri-20230930_lab.xml	Edgar Link	unprocessable
bfri-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BFRI
Biofrontera Inc. Stock $bfri

2023 Q4 Form 10-Q Financial Statement

#000149315223040132 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI Biofrontera Inc. Stock $bfri

2023 Q4 Form 10-Q Financial Statement

#000149315223040132 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI
Biofrontera Inc. Stock $bfri